1. Home
  2. ABTS vs AEMD Comparison

ABTS vs AEMD Comparison

Compare ABTS & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Abits Group Inc

ABTS

Abits Group Inc

HOLD

Current Price

$0.38

Market Cap

3.8M

Sector

Technology

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

SELL

Current Price

$5.55

Market Cap

3.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ABTS
AEMD
Founded
2010
1984
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.9M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
ABTS
AEMD
Price
$0.38
$5.55
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
★ $13.25
AVG Volume (30 Days)
★ 147.5K
49.5K
Earning Date
10-15-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.31
$0.53
52 Week High
$6.90
$25.66

Technical Indicators

Market Signals
Indicator
ABTS
AEMD
Relative Strength Index (RSI) 17.64 53.20
Support Level N/A $4.86
Resistance Level $1.56 $6.09
Average True Range (ATR) 0.12 0.36
MACD -0.07 -0.02
Stochastic Oscillator 9.76 47.69

Price Performance

Historical Comparison
ABTS
AEMD

About ABTS Abits Group Inc

Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: